Abstract:HIV-1 based lentiviral viruses are considered powerful and versatile gene therapy vectors to deliver therapeutic genes to patients with hereditary or acquired diseases. These vectors can efficiently transduce a variety of cell types when dividing or non-dividing to provide permanent delivery and long-term gene expression. Demand for scalable manufacturing protocols able to generate enough high titre vector for widespread use of this technology is increasing and considerable efforts to improve vector production cost-effectively, is ongoing. Current methods for LV production mainly use transient transfection of producer cell lines. Cells can be grown at scale, either in 2D relying on culturing producer cells in multi-tray flask cell culture factories or in roller bottles or can be adapted to grow in 3D suspensions in large batch fermenters. This suits rapid production and testing of new vector constructs pre-clinically for their efficacy, particle titre and safety. In this study, we sought to improve lentiviral titre over time by testing two alternative commercially available transfection reagents Fugene® 6 and Genejuice® with the commonly used polycation, polyethyleneimine. Our aim was to identify less cytotoxic transfection reagents that could be used to generate LV particles at high titre past the often used 72 hour period when vector is usually collected before producer cell death is caused due to post transfection cytotoxicity. We show that LV could be produced in extended culture using Genejuice® and even by transfected cells in glass flasks in suspension. Because this delivery agent is less toxic to 293T producer cells, following optimisation of transfection we found that LV can be harvested for more than 10 days at high titre. Using our protocol, titres of 10 9 TU/ml and 10 8 TU/ml were routinely reached via traditional monolayer conditions or suspension cultures, respectively. We propose, this simple change in vector production enables large volumes of high titre vector to be produced, cost effectively for non-clinical in vivo and in vitro applications or for more stringent downstream clinical grade vector purification.

A Quantitative Model for Efficient Construction of Lentiviral Vectors with a Unique Clone Site

Quantitative assessment on the cloning efficiencies of lentiviral transfer vectors with a unique clone site

Quantitative Models for Efficient Cloning of Different Vectors with Various Clone sites

Construct Recombinant Lentivirus Vector with Math1 and the Expression of Math1 in 293T Cells

A Single-Ltr HIV-1 Vector Optimized for Functional Genomics Applications

Construction and Identification of Lentiviral Vector-mediated RNA Interference of Epidermal Growth Factor Receptor

A Scalable Lentiviral Vector Production and Purification Method Using Mustang Q Chromatography and Tangential Flow Filtration

Efficient lentiviral transduction of different human and mouse cells

One-Step Construction of Lentiviral Reporter Using Red-Mediated Recombination

Engineering of HEK293T Cell Factory for Lentiviral Production by High-Throughput Selected Genes

Optimised protocols to generate high titre lentiviral vectors using a novel transfection agent enabling extended HEK293T culture following transient transfection and suspension culture

“Combinatorial Strategy”: A Highly Efficient Method for Cloning Different Vectors with Various Clone Sites

Rapid Construction of Complex Plant RNA Virus Infectious Cdna Clones for Agroinfection Using a Yeast-E. Coli-Agrobacterium Shuttle Vector

Stable expression of large transgenes via the knock-in of an integrase-deficient lentivirus

Construction of versatile low-copy-number vectors for cloning, sequencing and gene expression in Escherichia coli

Lentiviral Delivery of Proteins for Genome Engineering

Lentiviral vectors with two independent internal promoters transfer high-level expression of multiple transgenes to human hematopoietic stem-progenitor cells.

Generation of a stable packaging cell line producing high-titer PPT-deleted integration-deficient lentiviral vectors

Design and cloning strategies for constructing shRNA expression vectors

Efficient Molecular Biological Manipulations with Improved Strategies Based on Novel Escherichia Coli Vectors.

Comprehensive Untargeted Lipidomic Profiling of Third Generation Lentiviral Vectors and Packaging Cells